AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases

Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction

(2018) Leon Varjabedian et al.   American Journal of Cardiovascular Drugs

Metformin treatment decreases nitroxidative stress, restores nitric oxide bioavailability and endothelial function beyond glucose control

(2018) Takehiko Sambe et al.   BIOMEDICINE & PHARMACOTHERAPY

Metformin treatment prevents SREBP2-mediated cholesterol uptake and improves lipid homeostasis during oxidative stress-induced atherosclerosis

(2018) Raja Gopoju et al.   FREE RADICAL BIOLOGY AND MEDICINE

Activation of AMPK inhibits inflammatory response during hypoxia and reoxygenation through modulating JNK-mediated NF-κB pathway

(2018) Xu Chen et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

A potential strategy for treating atherosclerosis: improving endothelial function via AMP-activated protein kinase

(2018) Feng Gao et al.   Science China-Life Sciences

Gliclazide, a K ATP channel blocker, inhibits vascular smooth muscle cell proliferation through the CaMKKβ–AMPK pathway

(2018) Kyung Young Lee et al.   VASCULAR PHARMACOLOGY

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms

(2018) Sarah J. Mancini et al.   Scientific Reports

Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission

(2018) Hao Zhou et al.   Redox Biology

Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3β and p38α/MAPK in a rat model of diabetic cardiomyopathy

(2018) Nouf T. Al-Damry et al.   BIOMEDICINE & PHARMACOTHERAPY

Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study

(2018) Araz Rawshani et al.   LANCET

Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts

(2017) Tsung-Ming Lee et al.   FREE RADICAL BIOLOGY AND MEDICINE

Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat

(2017) Ya Zhang et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Dipeptidyl peptidase-4 inhibitor sitagliptin prevents high glucose-induced apoptosis via activation of AMP-activated protein kinase in endothelial cells

(2017) Chao Wu et al.   Molecular Medicine Reports

Liraglutide ameliorates cardiotoxicity induced by doxorubicin in rats through the Akt/GSK-3β signaling pathway

(2017) Noha A. T. Abbas et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects

(2017) Ioanna Andreadou et al.   Frontiers in Physiology

Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner

(2016) Rui Wei et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes

(2016) Ele Ferrannini et al.   DIABETES

The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels

(2016) Simon A. Hawley et al.   DIABETES

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

(2016) Ele Ferrannini et al.   DIABETES CARE

Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase

(2016) SONG-TAO TANG et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metformin Protects H9C2 Cardiomyocytes from High-Glucose and Hypoxia/Reoxygenation Injury via Inhibition of Reactive Oxygen Species Generation and Inflammatory Responses: Role of AMPK and JNK

(2016) Mingyan Hu et al.   Journal of Diabetes Research

Pleiotropic effects of acarbose on atherosclerosis development in rabbits are mediated via upregulating AMPK signals

(2016) Kuei-Chuan Chan et al.   Scientific Reports

GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats

(2015) Tomoaki Inoue et al.   ATHEROSCLEROSIS

Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation

(2015) Yue Zhou et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Targeted deletion of PTEN in cardiomyocytes renders cardiac contractile dysfunction through interruption of Pink1–AMPK signaling and autophagy

(2015) Nathan D. Roe et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association

(2015) Caroline S. Fox et al.   DIABETES CARE

SGLT2 Inhibitors May Predispose to Ketoacidosis

(2015) Simeon I. Taylor et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

(2015) Faiez Zannad et al.   LANCET

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is AMPK the savior of the failing heart?

(2015) Ty T. Kim et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect

(2015) Yoshifumi Saisho   Endocrine Metabolic & Immune Disorders-Drug Targets

AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes

(2014) Magali Balteau et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Exposure to rosiglitazone, a PPAR-γ agonist, in late gestation reduces the abundance of factors regulating cardiac metabolism and cardiomyocyte size in the sheep fetus

(2014) Shervi Lie et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms

(2014) Yanmei Zeng et al.   Cardiovascular Diabetology

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

(2014) Bowen Lin et al.   Cardiovascular Diabetology

Role of Epac2A/Rap1 Signaling in Interplay Between Incretin and Sulfonylurea in Insulin Secretion

(2014) Harumi Takahashi et al.   DIABETES

Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction

(2014) Hamid Soraya et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism

(2014) Nadia M. Krasner et al.   PLoS One

Metformin Protects Cardiomyocyte from Doxorubicin Induced Cytotoxicity through an AMP-Activated Protein Kinase Dependent Signaling Pathway: An In Vitro Study

(2014) Laura C. Kobashigawa et al.   PLoS One

Effect of exenatide on the cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits and heart function in streptozotocin-induced diabetic rats

(2014) Zhixin Guo et al.   Diabetology & Metabolic Syndrome

Mulberry 1-Deoxynojirimycin Pleiotropically Inhibits Glucose-Stimulated Vascular Smooth Muscle Cell Migration by Activation of AMPK/RhoB and Down-regulation of FAK

(2013) Kuei-Chuan Chan et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

AMPK, insulin resistance, and the metabolic syndrome

(2013) Neil B. Ruderman et al.   JOURNAL OF CLINICAL INVESTIGATION

The Cardiovascular Safety of Diabetes Drugs — Insights from the Rosiglitazone Experience

(2013) William R. Hiatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

AMP-Activated Protein Kinase: A Target for Drugs both Ancient and Modern

(2012) D. Grahame Hardie et al.   CHEMISTRY & BIOLOGY

A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity

(2012) Mohammad Hossein Noyan-Ashraf et al.   CIRCULATION

Early Improvement in Carotid Plaque Echogenicity by Acarbose in Patients With Acute Coronary Syndromes

(2012) Mitsumasa Hirano et al.   CIRCULATION JOURNAL

Dissociation of Bcl-2-Beclin1 Complex by Activated AMPK Enhances Cardiac Autophagy and Protects Against Cardiomyocyte Apoptosis in Diabetes

(2012) C. He et al.   DIABETES

Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe −/− mice

(2012) F. Vittone et al.   DIABETOLOGIA

Short-term treatment with metformin suppresses toll like receptors (TLRs) activity in isoproterenol-induced myocardial infarction in rat: Are AMPK and TLRs connected?

(2012) Hamid Soraya et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Miglitol, an Anti-diabetic Drug, Inhibits Oxidative Stress^|^ndash;Induced Apoptosis and Mitochondrial ROS Over-Production in Endothelial Cells by Enhancement of AMP-Activated Protein Kinase

(2012) Chie Aoki et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies

(2012) Nancy J. Brown   Journal of the American Society of Hypertension

The effect of glucagon-like peptide 1 on cardiovascular risk

(2012) Jacob Sivertsen et al.   Nature Reviews Cardiology

Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure

(2011) Meimei Yin et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice

(2011) Alex Morrison et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy

(2011) Zhonglin Xie et al.   Autophagy

The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury

(2011) Yumei Ye et al.   BASIC RESEARCH IN CARDIOLOGY

Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis

(2011) Zubair Shah et al.   CIRCULATION

Improvement of Cardiac Functions by Chronic Metformin Treatment Is Associated With Enhanced Cardiac Autophagy in Diabetic OVE26 Mice

(2011) Z. Xie et al.   DIABETES

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

(2011) Tina Ken Schramm et al.   EUROPEAN HEART JOURNAL

Metformin protects against doxorubicin-induced cardiotoxicity: Involvement of the adiponectin cardiac system

(2011) Mari C. Asensio-López et al.   FREE RADICAL BIOLOGY AND MEDICINE

Effects of DPP-4 inhibition on cardiac metabolism and function in mice

(2011) M. Lenski et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Activated protein C protects against myocardial ischemic/reperfusion injury through AMP-activated protein kinase signaling

(2011) J. WANG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

AMP-Activated Protein Kinase Activation during Cardioplegia-Induced Hypoxia/Reoxygenation Injury Attenuates Cardiomyocytic Apoptosis via Reduction of Endoplasmic Reticulum Stress

(2011) Chi-Hsiao Yeh et al.   MEDIATORS OF INFLAMMATION

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA

(2010) Yumei Ye et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats

(2010) Barbara Huisamen et al.   CARDIOVASCULAR DRUGS AND THERAPY

Transitory Activation of AMPK at Reperfusion Protects the Ischaemic-Reperfused Rat Myocardium Against Infarction

(2010) Marta A. Paiva et al.   CARDIOVASCULAR DRUGS AND THERAPY

Impaired Macrophage Migration Inhibitory Factor–AMP-Activated Protein Kinase Activation and Ischemic Recovery in the Senescent Heart

(2010) Heng Ma et al.   CIRCULATION

Intensive Glucose Lowering and Cardiovascular Disease Prevention in Diabetes

(2010) Theodore Mazzone   CIRCULATION

Metformin improves cardiac function in rats via activation of AMP-activated protein kinase

(2010) Xiao-Fang Wang et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database

(2010) E. S. Horton et al.   DIABETES CARE

The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A retrospective analysis

(2010) K. M. Pantalone et al.   DIABETES CARE

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database

(2010) J. H. Best et al.   DIABETES CARE

Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone

(2010) David J. Graham et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antidiabetic Drug Voglibose Is Protective Against Ischemia—Reperfusion Injury Through Glucagon-Like Peptide 1 Receptors and the Phosphoinositide 3-Kinase-Akt-Endothelial Nitric Oxide Synthase Pathway in Rabbits

(2010) Masamitsu Iwasa et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Effects of Mulberry Leaf Extract Rich in 1-Deoxynojirimycin on Blood Lipid Profiles in Humans

(2010) Yoshihiro Kojima et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION

Autophagy: cellular and molecular mechanisms

(2010) Danielle Glick et al.   JOURNAL OF PATHOLOGY

Metformin Prevents Progression of Heart Failure in Dogs

(2009) Hideyuki Sasaki et al.   CIRCULATION

Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?

(2009) N. Papanas et al.   CURRENT PHARMACEUTICAL DESIGN

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

Global estimates of the prevalence of diabetes for 2010 and 2030

(2009) J.E. Shaw et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Evidence for the Importance of Adiponectin in the Cardioprotective Effects of Pioglitazone

(2009) Ping Li et al.   HYPERTENSION

Acarbose Reduces Myocardial Infarct Size by Preventing Postprandial Hyperglycemia and Hydroxyl Radical Production and Opening Mitochondrial KATP Channels in Rabbits

(2009) Shinya Minatoguchi et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Metformin Prevents Myocardial Reperfusion Injury by Activating the Adenosine Receptor

(2009) Marta Paiva et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt

(2009) Mayuko F Kato et al.   JOURNAL OF HYPERTENSION

Peroxisome proliferator-activated receptors γ and α agonists stimulate cardiac glucose uptake via activation of AMP-activated protein kinase☆

(2009) Xiaoyan Xiao et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

AMPK in Health and Disease

(2009) Gregory R. Steinberg et al.   PHYSIOLOGICAL REVIEWS

Metformin: safety in cardiac patients

(2009) R. Khurana et al.   POSTGRADUATE MEDICAL JOURNAL

Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms

(2008) Ramesh Saeedi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure

(2008) Susheel Gundewar et al.   CIRCULATION RESEARCH

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart

(2008) Edward J. Miller et al.   NATURE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease

(2007) C. A. Schneider et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY